Tredje AP fonden Grows Position in Illumina, Inc. $ILMN

Tredje AP fonden raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 112.0% in the second quarter, Holdings Channel.com reports. The institutional investor owned 26,155 shares of the life sciences company’s stock after purchasing an additional 13,818 shares during the quarter. Tredje AP fonden’s holdings in Illumina were worth $2,495,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Envestnet Portfolio Solutions Inc. grew its stake in Illumina by 0.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 99 shares in the last quarter. Moors & Cabot Inc. grew its position in shares of Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after purchasing an additional 145 shares in the last quarter. Arkadios Wealth Advisors grew its position in shares of Illumina by 1.7% in the second quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock valued at $871,000 after purchasing an additional 157 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock valued at $445,000 after purchasing an additional 164 shares in the last quarter. Finally, Whipplewood Advisors LLC grew its position in shares of Illumina by 22.2% in the second quarter. Whipplewood Advisors LLC now owns 929 shares of the life sciences company’s stock valued at $89,000 after purchasing an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several analyst reports. Cowen restated a “hold” rating on shares of Illumina in a report on Friday. UBS Group upped their price objective on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Friday. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Scotiabank cut shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a research note on Friday, July 11th. Finally, Robert W. Baird set a $109.00 price target on shares of Illumina in a research note on Friday. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $115.00.

Illumina Trading Up 24.9%

Shares of ILMN stock opened at $123.64 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market cap of $19.00 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 2.34 and a beta of 1.40. The company has a 50-day moving average of $98.41 and a two-hundred day moving average of $92.90. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.